173 related articles for article (PubMed ID: 32940377)
1. Quantification of cancer driver mutations in human breast and lung DNA using targeted, error-corrected CarcSeq.
Harris KL; Walia V; Gong B; McKim KL; Myers MB; Xu J; Parsons BL
Environ Mol Mutagen; 2020 Nov; 61(9):872-889. PubMed ID: 32940377
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clonal Expansion Using CarcSeq Measurement of Lung Cancer Driver Mutations and Correlation With Mouse Strain- and Sex-Related Incidence of Spontaneous Lung Neoplasia.
Harris KL; McKim KL; Myers MB; Gong B; Xu J; Parsons BL
Toxicol Sci; 2021 Oct; 184(1):1-14. PubMed ID: 34373914
[TBL] [Abstract][Full Text] [Related]
3. CarcSeq Measurement of Rat Mammary Cancer Driver Mutations and Relation to Spontaneous Mammary Neoplasia.
McKim KL; Myers MB; Harris KL; Gong B; Xu J; Parsons BL
Toxicol Sci; 2021 Jul; 182(1):142-158. PubMed ID: 33822199
[TBL] [Abstract][Full Text] [Related]
4. Rationale and Roadmap for Developing Panels of Hotspot Cancer Driver Gene Mutations as Biomarkers of Cancer Risk.
Harris KL; Myers MB; McKim KL; Elespuru RK; Parsons BL
Environ Mol Mutagen; 2020 Jan; 61(1):152-175. PubMed ID: 31469467
[TBL] [Abstract][Full Text] [Related]
5. Variation in organ-specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas.
Parsons BL; McKim KL; Myers MB
Environ Mol Mutagen; 2017 Aug; 58(7):466-476. PubMed ID: 28755461
[TBL] [Abstract][Full Text] [Related]
6. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
[TBL] [Abstract][Full Text] [Related]
7. ACB-PCR Quantification of Low-Frequency Hotspot Cancer-Driver Mutations.
Myers MB; McKim KL; Wang Y; Banda M; Parsons BL
Methods Mol Biol; 2020; 2102():395-417. PubMed ID: 31989569
[TBL] [Abstract][Full Text] [Related]
8. Low-Frequency Mutational Heterogeneity of Invasive Ductal Carcinoma Subtypes: Information to Direct Precision Oncology.
Myers MB; McKim KL; Banda M; George NI; Parsons BL
Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30813596
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project.
Kerr KM; Dafni U; Schulze K; Thunnissen E; Bubendorf L; Hager H; Finn S; Biernat W; Vliegen L; Losa JH; Marchetti A; Cheney R; Warth A; Speel EJ; Blackhall F; Monkhorst K; Jantus Lewintre E; Tischler V; Clark C; Bertran-Alamillo J; Meldgaard P; Gately K; Wrona A; Vandenberghe P; Felip E; De Luca G; Savic S; Muley T; Smit EF; Dingemans AC; Priest L; Baas P; Camps C; Weder W; Polydoropoulou V; Geiger TR; Kammler R; Sumiyoshi T; Molina MA; Shames DS; Stahel RA; Peters S;
Ann Oncol; 2018 Jan; 29(1):200-208. PubMed ID: 29186353
[TBL] [Abstract][Full Text] [Related]
10. Lifespan Kras mutation levels in lung and liver of B6C3F
McKinzie PB; McKim KL; Pearce MG; Bishop ME; Parsons BL
Environ Mol Mutagen; 2018 Oct; 59(8):715-721. PubMed ID: 30255594
[TBL] [Abstract][Full Text] [Related]
11. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
Li BT; Janku F; Jung B; Hou C; Madwani K; Alden R; Razavi P; Reis-Filho JS; Shen R; Isbell JM; Blocker AW; Eattock N; Gnerre S; Satya RV; Xu H; Zhao C; Hall MP; Hu Y; Sehnert AJ; Brown D; Ladanyi M; Rudin CM; Hunkapiller N; Feeney N; Mills GB; Paweletz CP; Janne PA; Solit DB; Riely GJ; Aravanis A; Oxnard GR
Ann Oncol; 2019 Apr; 30(4):597-603. PubMed ID: 30891595
[TBL] [Abstract][Full Text] [Related]
12. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).
Aisner DL; Sholl LM; Berry LD; Rossi MR; Chen H; Fujimoto J; Moreira AL; Ramalingam SS; Villaruz LC; Otterson GA; Haura E; Politi K; Glisson B; Cetnar J; Garon EB; Schiller J; Waqar SN; Sequist LV; Brahmer J; Shyr Y; Kugler K; Wistuba II; Johnson BE; Minna JD; Kris MG; Bunn PA; Kwiatkowski DJ;
Clin Cancer Res; 2018 Mar; 24(5):1038-1047. PubMed ID: 29217530
[No Abstract] [Full Text] [Related]
13. Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
Craig DJ; Morrison T; Khuder SA; Crawford EL; Wu L; Xu J; Blomquist TM; Willey JC
BMC Cancer; 2019 Nov; 19(1):1081. PubMed ID: 31711466
[TBL] [Abstract][Full Text] [Related]
14. Quantification of Kras mutant fraction in the lung DNA of mice exposed to aerosolized particulate vanadium pentoxide by inhalation.
Banda M; McKim KL; Haber LT; MacGregor JA; Gollapudi BB; Parsons BL
Mutat Res Genet Toxicol Environ Mutagen; 2015 Aug; 789-790():53-60. PubMed ID: 26232258
[TBL] [Abstract][Full Text] [Related]
15. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
16. Genomic variations in plasma cell free DNA differentiate early stage lung cancers from normal controls.
Xia S; Huang CC; Le M; Dittmar R; Du M; Yuan T; Guo Y; Wang Y; Wang X; Tsai S; Suster S; Mackinnon AC; Wang L
Lung Cancer; 2015 Oct; 90(1):78-84. PubMed ID: 26233568
[TBL] [Abstract][Full Text] [Related]
17. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
18. Predicting osimertinib-treatment outcomes through EGFR mutant-fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L).
Sakai K; Takahama T; Shimokawa M; Azuma K; Takeda M; Kato T; Daga H; Okamoto I; Akamatsu H; Teraoka S; Ono A; Ohira T; Yokoyama T; Yamamoto N; Nakagawa K; Nishio K
Mol Oncol; 2021 Jan; 15(1):126-137. PubMed ID: 33131198
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice.
Mirsalis JC; Shimon JA; Johnson A; Fairchild D; Kanazawa N; Nguyen T; de Boer J; Glickman B; Winegar RA
Environ Mol Mutagen; 2005; 45(1):17-35. PubMed ID: 15605353
[TBL] [Abstract][Full Text] [Related]
20. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
